Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?

Specific ADCs: HER2, HER3, CEACAM5, MET

Date

15 Sep 2024

Session

Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?

Topics

Targeted Therapy;  Molecular Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

David Planchard

Authors

D. Planchard

Author affiliations

  • Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Resistance and sequencing to ADCs

Presenter: Leif Ellisen

Session: Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?

Resources:

Slides

Webcast

Toxicity of ADCs

Presenter: Anne-Marie Dingemans

Session: Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?

Resources:

Slides

Webcast

Q&A and discussion

Session: Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.